Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + docetaxel + 5-fluorouracil + oxaliplatin + interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Benaroya Research Institute
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This therapeutic regimen is a multi-agent protocol developed and studied by the Benaroya Research Institute for the treatment of borderline resectable or locally advanced pancreatic adenocarcinoma. The protocol typically involves induction chemotherapy using gemcitabine and docetaxel, followed by a chemoradiation phase consisting of oxaliplatin, 5-fluorouracil (5-FU), and interferon alfa-2b, often culminating in surgical resection (pancreaticoduodenectomy). Gemcitabine and 5-FU are antimetabolites that inhibit DNA synthesis, while docetaxel is a taxane that stabilizes microtubules to arrest cell division. Oxaliplatin acts as a platinum-based DNA alkylating agent that induces lethal cross-links. Interferon alfa-2b is utilized as a biological response modifier to enhance the cytotoxic and radiosensitizing effects of the chemotherapy. This intensive multi-modality approach is designed to downstage tumors and improve the likelihood of achieving curative-intent surgical outcomes.
- Other names
- Gemcitabine/Docetaxel and Oxaliplatin-Based ChemoradiationVirginia Mason ProtocolBenaroya Protocol
02
Targets
RNR (Ribonucleotide reductase)TS (Thymidylate synthase)DNA polymerase familyDNA
Beyond the preview
Go deeper on gemcitabine + docetaxel + 5-fluorouracil + oxaliplatin + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + docetaxel + 5-fluorouracil + oxaliplatin + interferon alfa-2b.